Introduction
============

Epit helial ovarian cancer (EOC) remains the gynecological cancer with the highest mortality because over two-thirds of patients have advanced disease upon diagnosis \[[@b1-crt-2016-135]\]. Only 10% of cases are due to an inherited predisposition, while the majority are attributable to alterations in BRCA1 and *BRCA2*, which present the strongest risk factors for breast and ovarian cancers \[[@b2-crt-2016-135]\]. Indeed, studies of lifetime risk of ovarian cancer have revealed that it ranges from 39% to 54% in women identified as having a *BRCA1/2* mutation, with lower risk associated with *BRCA2* mutation than *BRCA1* \[[@b3-crt-2016-135]\].

Most patients with *BRCA1/2* mutations have a demonstrably more favorable outcome than those with sporadic ovarian cancers \[[@b4-crt-2016-135],[@b5-crt-2016-135]\]. However, the mechanism of this purported survival advantage conferred by *BRCA1/2* mutation is not entirely clear. Some have speculated that it results from a greater susceptibility to chemotherapy owing to a significantly higher growth fraction in *BRCA1/2*-associated malignancies \[[@b6-crt-2016-135]\]. However, others have not been able to confirm the significant survival advantage conferred by *BRCA1/2* mutations, specifically in terms of long term overall survival (OS) \[[@b7-crt-2016-135],[@b8-crt-2016-135]\]. Indeed, poorer survival for patients with *BRCA1/2* mutations has been reported \[[@b9-crt-2016-135],[@b10-crt-2016-135]\], although it remains unclear why different investigators have noted such varying effects of *BRCA1/2* alterations on survival.

Several previous studies of *BRCA1/2* and EOC have been conducted in Korea, and *BRCA1/2* mutations were found in 33% of patients with a strong family history of EOC \[[@b11-crt-2016-135],[@b12-crt-2016-135]\]. Possible candidates of a founder mutation in Korea have also been reported \[[@b13-crt-2016-135]\]. Moreover, a large, prospective, nationwide study of Korean breast cancer patients and their *BRCA1/2* status suggested that *BRCA1* mutation has a significant negative impact on survival \[[@b14-crt-2016-135]\]. However, only a few studies have analyzed the effects of *BRCA1/2* mutation status on the clinical prognosis of EOC patients of Asian ethnicity \[[@b15-crt-2016-135]\]. Furthermore, clinical features of EOC patients who have a *BRCA1/2* variant of uncertain significance (VUS), which is a gene mutation that has an unknown effect on protein function, have not been reported to date \[[@b16-crt-2016-135]\]. The potential for an alternate interpretation of a *BRCA1/2* VUS over time carries with it possible disparate clinical implications. Thus, characterization of patients with *BRCA1/2* VUS is required for counseling and follow-up.

Therefore, this study was conducted to investigate clinical features of EOC patients according to *BRCA1/2* mutation status (*BRCA1/2* mutation vs. *BRCA1/2* VUS vs. *BRCA1/2* wild type), including survival.

Materials and Methods
=====================

1. Patient selection and pathologic review
------------------------------------------

The study protocol was approved by the Institutional Review Board. During the review of medical records, we obtained data describing several patient characteristics, including age at diagnosis, histologic type, and surgical stage as classified by the International Federation of Gynecology and Obstetrics criteria.

A patient selection diagram is shown in [Fig. 1](#f1-crt-2016-135){ref-type="fig"}. A total of 711 patients were pathologically confirmed to have EOC from January 1999 to May 2015. Of these, 595 had uninformative *BRCA1/2* mutation statuses and were therefore excluded. A *BRCA1/2* genetic test was performed for the remaining 116 patients. A gynecologic oncology team at a single institute conducted all procedures, and a dedicated radiologist at the same institute reviewed all data from imaging studies (e.g., magnetic resonance imaging and computed tomography). From 2011, neoadjuvant chemotherapy followed by interval debulking surgery was introduced in our institution, and 39 out of the 116 patients received this treatment. All 116 patients were treated with platinum based chemotherapy. These patients were analyzed for mutation type and clinical features including family history, personal breast cancer history, progression-free survival (PFS), OS, and response rate.

The response rate was determined using the Response Evaluation Criteria in Solid Tumors system. Specifically, we analyzed PFS and OS in patients with *BRCA1/2* mutation and compared these data with those of patients with *BRCA1/2* wild type and VUS. PFS was defined as the period in months between the dates of diagnosis and relapse or last contact. OS was defined as the period in months between the dates of diagnosis and death or last contact.

2. Direct sequencing
--------------------

Genetic testing for BRCA1 and *BRCA2* (accession numbers NM_007294 and NM_000059, respectively) mutations was performed using direct sequencing as previously described \[[@b12-crt-2016-135]\]. The genetic mutations analyzed were confined to deleterious mutations such as frameshift or nonsense mutations. Variations were described following the nomenclature system of the Human Genome Variation Society (<http://www.hgvs.org/mutnomen>) and the conventional nomenclature system from the Breast Cancer Information Core (BIC; <http://research.nhgri.nih.gov/bic/>).

3. Statistical analysis
-----------------------

Statistical analysis was performed using IBM SPSS ver. 20.0 (IBM Corp., Armonk, NY). A Kolmogorov-Smirnov test was used to verify standard normal distributional assumptions. Patient clinical features including response rate, PFS, and OS were analyzed using an ANOVA test, a Pearson's chi-squared test, and Kaplan-Meier survival analysis. A p-value of less than 0.05 was regarded as statistically significant.

Results
=======

1. Patient characteristics
--------------------------

Patient characteristics are shown in [Table 1](#t1-crt-2016-135){ref-type="table"}. Among the 116 EOC patients who underwent *BRCA1/2* gene tests by the polymerase chain reaction--denaturing high performance liquid chromatography--sequencing method, 37 (37/116, 31.9%) *BRCA1/2* mutations were identified (BRCA1, 30; *BRCA2*, 7). In addition, 25 patients with *BRCA1/2* VUSs were identified (25/116, 21.6%) and two different types of *BRCA1/2* VUS were found simultaneously in one patient.

No significant differences were detected in terms of mean age, International Federation of Gynecology and Obstetrics stage, cancer histology, grade, and performance of optimal surgery. Personal histories of breast cancer were observed in 48.6% of patients with *BRCA1/2* mutation (18/37), 16.0% of patients with *BRCA1/2* VUS (4/25), and 7.4% of those with wild type (4/54) (p \< 0.001). A family history of *BRCA1/2*-associated cancer was present in 48.6% of patients with *BRCA1/2* mutation (18/37), 36.0% of those with *BRCA1/2* VUS (9/25), and 37% of *BRCA1/2* patients with *BRCA* wild type (20/54) (p=0.299).

2. Response rates and survival
------------------------------

The response rate was 83.8% in patients with *BRCA1/2* mutation (31/37), 88.0% in patients with *BRCA1/2* VUS (22/25), and 85.2% in patients with *BRCA1/2* wild type (46/54). No significant differences were detected between the three groups (p=0.898) ([Table 2](#t2-crt-2016-135){ref-type="table"}).

The median PFS was 17, 14, and 13 months for patients with *BRCA1/2* mutation, VUS, and wild type, respectively. Patients with *BRCA1/2* mutation had longer PFS than those with *BRCA1/2* wild type, although this difference did not achieve statistical significance (p=0.071). No significant differences were detected in terms of PFS between patients with *BRCA1/2* VUS and *BRCA1/2* mutation or wild type (p=0.772 and p=0.455, respectively) ([Fig. 2](#f2-crt-2016-135){ref-type="fig"}).

The median OS was 33, 24, and 17 months in patients with *BRCA1/2* mutation, VUS, and wild type, respectively. Patients with *BRCA1/2* mutation showed longer OS than those with *BRCA1/2* wild type (p=0.005). No significant differences were detected in OS between patients with *BRCA1/2* VUS and *BRCA1/2* mutation or wild type (p=0.459 and p=0.211, respectively) ([Fig. 3](#f3-crt-2016-135){ref-type="fig"}).

3. Frequently observed *BRCA1/2* alterations
--------------------------------------------

Frequently observed *BRCA1/2* alterations in this study are presented in [Tables 3](#t3-crt-2016-135){ref-type="table"} and [4](#t4-crt-2016-135){ref-type="table"}. The c.3627_3628insA (p.Leu1209 \_Glu1210?fs) alteration in *BRCA1* (exon 11) was recurrent in five patients (5/37, 13.5%). Among the 25 patients with *BRCA1/2* VUS, c.8187G\>T (p.Lys2729Asn) mutation in *BRCA2* (exon 18) was present in four (4/25, 16%). All of the frequently observed alterations were reported in the Breast Cancer Information Core database.

Discussion
==========

In the present study, we investigated the impact of *BRCA1/2* mutation status on the clinical features of EOC patients. Patients with *BRCA1/2* mutation had improved OS as compared to those with *BRCA1/2* wild type. However, no significant differences in PFS and response rates were detected between the groups included in this study. *BRCA1/2* mutation and VUS patients had similar prognoses. Greater sensitivity to platinum-based chemotherapy among patients with *BRCA1/2* mutation was not identified in this study. To the best of our knowledge, this is the first study that compared the clinical outcomes of EOC patients with *BRCA1/2* mutation, VUS, and wild type.

A favorable prognosis for patients with *BRCA1/2* mutation over that of patients with *BRCA1/2* wild type was identified in this study, although no significant difference was detected in PFS. The underlying mechanism of *BRCA1/2* mutation conferring a favorable prognosis remains unclear. The main function of *BRCA1/2* proteins is to promote DNA double-strand break repair via homologous recombination. *BRCA1* has been implicated in many cellular functions, including DNA repair, the maintenance of genomic integrity, and cell cycle checkpoint control \[[@b17-crt-2016-135],[@b18-crt-2016-135]\]. The main function of *BRCA2* appears to involve interaction with RAD51 during homologous recombination DNA repair \[[@b19-crt-2016-135]\]. Cells with mutated *BRCA1/2* proteins may therefore be rendered less capable of repairing chemotherapy-induced DNA damage, potentially leading to an improved response to treatment. This is known as \'synthetic lethality,\' i.e., the enhanced lethality of DNA-damaging agents.

Our data failed to show significantly longer PFS or a better response rate to chemotherapy in patients with *BRCA1/2* mutation over those of patients with *BRCA1/2* VUS or wild type. To explain the discrepancy between our data and those of prior studies, a more complex model is necessary to clarify specific mechanisms of *BRCA1/2* dysfunction that result in better outcomes for EOC patients. It is estimated that approximately 50% of sporadic EOCs show *BRCA1* or *BRCA2* dysfunction through different mechanisms. Tumors that share molecular features of *BRCA1/2*-mutant tumors (i.e., BRCAness) could also emerge in this process that affects or is affected by normal *BRCA1/2* gene function \[[@b20-crt-2016-135],[@b21-crt-2016-135]\]. Previous studies reported that low *BRCA1* or *BRCA2* expression in sporadic EOC could confer similar effects on prognosis as *BRCA1* or *BRCA2* mutation. Specifically, low *BRCA1* expression measured by reverse transcription polymerase chain reaction was shown to be a positive prognostic factor for both OS and PFS in patients with sporadic EOCs \[[@b22-crt-2016-135]\]. This finding indicates that low *BRCA1* expression status in sporadic EOC has a similar impact on prognosis as germline *BRCA1/2* mutation. Therefore, if "BRCAness" could be measured quantitatively in our study, a precise comparison between "BRCAness" positive and negative groups would possible.

Interpretation of the clinical implications of *BRCA1/2* VUS remains challenging because misperception by a physician regarding the implications of VUS could lead to inappropriate risk-reducing surgery, neglect, or providing misinformation to patients. Myriad Genetic Laboratories (Salt Lake City, UT) reported that about 7% of their molecular diagnoses of hereditary breast and ovarian cancer are linked to VUSs \[[@b23-crt-2016-135],[@b24-crt-2016-135]\], and these alterations have been identified more commonly in African-American than in Hispanic populations \[[@b25-crt-2016-135],[@b26-crt-2016-135]\]. However, few reports have analyzed VUS prevalence in Asian patients. Additionally, limited information is available regarding the clinical features of EOC patients with *BRCA1/2* VUS.

Despite the possibility of selection bias, 21.6% of patients (25/116) who underwent *BRCA1/2* genetic tests were found to have *BRCA1/2* VUS. Among patients with *BRCA1/2* VUS, 16% (4/25) had a personal history of double primary breast cancer and 36% (9/25) had a family history of breast or ovarian cancer in first-degree relatives. One of the VUSs found in this study (*BRCA1* c.5339T\>C) is highly suspected to be a deleterious mutation based on the patients' family histories of *BRCA1/2*-associated cancer, personal histories of breast cancer, and population frequency.

Identification of founder mutations is required to improve the quality of genetic counseling. Moreover, using a more specific approach to molecular testing leads to greater cost-effectiveness. If we can recognize differences in susceptibility due to a specific founder mutation, it will be possible to define the role of risk reducing surgery. Frequently observed alterations in this study are presented in [Tables 3](#t3-crt-2016-135){ref-type="table"} and [4](#t4-crt-2016-135){ref-type="table"}. Studies to identify founder mutations have been conducted in Asian countries \[[@b27-crt-2016-135]\], and one report analyzed possible candidates of a founder mutation in Korea \[[@b13-crt-2016-135]\]. However, specific mutations that account for a high frequency of cases, such as that observed in the Ashkenazi Jewish population, have not yet been discovered. The frequently observed *BRCA1/2* alterations found in this study were not identified in a previous study conducted in Korea. Accordingly, an investigation including a larger number of cases must be analyzed to provide accurate information regarding the frequency of founder mutations.

It should be noted that this study had several limitations. Specifically, it included a small number of patients with *BRCA1/2* mutations because of the low rate of genetic testing, had a retrospective design with the possibility of selection bias, and a short follow-up period. Moreover, 595 patients declined *BRCA1/2* genetic testing. Conversely, a previous report showed few barriers to participating in genetic counseling and *BRCA1/2* testing in Western countries, with a testing rate of 81% \[[@b28-crt-2016-135]\]. The low rate of genetic testing (16.3%, 116/711) in the present study may be the result of low public awareness regarding its availability. In addition, this study included patients representative of a cancer center population, and all study participants had been affected by EOC. Thus, our findings may not apply to patients who have not had cancer and are undergoing genetic testing due to family history alone.

Routine tests for *BRCA1/2* germline mutation status in patients with EOC may be warranted, as it has been demonstrated that a deficiency in the *BRCA1/2* gene confers substantial sensitivity to a chemotherapeutic agent, namely poly(ADP-ribose) polymerase-1 (PARP) inhibitor (olaparib) \[[@b29-crt-2016-135]\]. Further research is required to determine whether application of this agent to EOCs with pathologic *BRCA1/2* VUS is beneficial or not. Some patients with *BRCA1/2* VUS may be responsive to treatment with PARP inhibitors, which results in synthetic lethality of cells that have deficient homologous recombination or double-strand DNA repair. This might improve survival among such patients. Further prospective cohort studies with longer follow-up periods as well as "BRCAness" quantification are needed to enable a precise understanding of the role of BRCAness on the clinical features of EOC patients.

Conclusion
==========

Our study provides useful data for counseling EOC patients with *BRCA1/2* mutation, VUS, and wild type. Patients with *BRCA1/2* mutation had more favorable prognosis, or significantly longer OS than those with *BRCA1/2* wild type, while they have similar prognoses as patients with *BRCA1/2* VUS.
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![Patient selection diagram. VUS, variant of uncertain significance.](crt-2016-135f1){#f1-crt-2016-135}

![Progression-free survival (PFS) curves according to *BRCA1/2* mutation status. Median PFS was 17 months for *BRCA1/2* mutation patients, 14 months for *BRCA1/2* variant of uncertain significance (VUS) patients, and 13 months for *BRCA1/2* wild type patients. A log-rank test revealed longer PFS for *BRCA1/2*mutation than wild type patients; however, this was not statistically significant (p=0.071). No differences were detected between *BRCA1/2* wild type and VUS (p=0.455) or *BRCA1/2* mutation and VUS (p=0.772).](crt-2016-135f2){#f2-crt-2016-135}

![Overall survival (OS) curves according to *BRCA1/2* mutation status. Median OS was 33 months for *BRCA1/2* mutation patients, 24 months for *BRCA1/2* variant of uncertain significance (VUS) patients, and 17 months for *BRCA1/2* wild type patients. A log-rank test revealed significantly longer OS for *BRCA1/2*mutation than wild type patients (p=0.005). No differences were detected between *BRCA1/2* wild type and VUS (p=0.211) or *BRCA1/2* mutation and VUS (p=0.459).](crt-2016-135f3){#f3-crt-2016-135}

###### 

Patient characteristics

  Characteristic                                Overall population (n=116)   *BRCA1/2* mutation (n=37)   *BRCA1/2* VUS (n=25)   *BRCA1/2* wild type (n=54)   p-value
  --------------------------------------------- ---------------------------- --------------------------- ---------------------- ---------------------------- ---------------------------------------------------------
  **Age**                                                                                                                                                    
   Mean±SD                                      52.2±11.4                    52.4±9.3                    52.0±11.6              52.2±12.8                    0.99^[a)](#tfn1-crt-2016-135){ref-type="table-fn"}^
  **Stage FIGO**                                                                                                                                             
   I-II                                         21 (18.1)                    2 (5.4)                     6 (24.0)               13 (24.1)                    0.059^[b)](#tfn2-crt-2016-135){ref-type="table-fn"}^
   III-IV                                       94 (81.0)                    34 (91.9)                   19 (76.0)              41 (75.9)                    
   NI                                           1 (0.9)                      1 (2.7)                     0                      0                            
  **Histology**                                                                                                                                              
   Serous                                       91 (78.4)                    32 (86.5)                   18 (72.0)              41 (75.9)                    0.198^[b)](#tfn2-crt-2016-135){ref-type="table-fn"}^
   Mucinous                                     8 (6.9)                      0                           2 (8.0)                6 (11.1)                     
   Endometrioid                                 5 (4.3)                      0                           2 (8.0)                3 (5.6)                      
   Clear cells                                  5 (4.3)                      0                           1 (4.0)                4 (7.4)                      
   Others                                       3 (2.6)                      2 (5.4)                     1 (4.0)                0                            
   NI                                           4 (3.4)                      3 (8.1)                     1 (4.0)                0                            
  **Grade**                                                                                                                                                  
   02-1                                         45 (38.8)                    9 (24.3)                    10 (40.0)              26 (48.1)                    0.260^[b)](#tfn2-crt-2016-135){ref-type="table-fn"}^
   3                                            60 (51.7)                    23 (62.2)                   14 (56.0)              23 (42.6)                    
   NI                                           11 (9.5)                     5 (13.5)                    1 (4.0)                5 (9.3)                      
  **Optimal surgery**                                                                                                                                        
   Yes                                          82 (70.7)                    22 (59.5)                   20 (80.0)              40 (74.1)                    0.130^[b)](#tfn2-crt-2016-135){ref-type="table-fn"}^
   No                                           22 (19.0)                    11 (29.7)                   0                      11 (20.4)                    
   NI                                           12 (10.3)                    4 (10.8)                    5 (20.0)               3 (5.6)                      
  **Personal history of breast cancer**                                                                                                                      
   Yes                                          26 (22.4)                    18 (48.6)                   4 (16.0)               4 (7.4)                      \< 0.001^[b)](#tfn2-crt-2016-135){ref-type="table-fn"}^
   No                                           89 (76.7)                    18 (48.6)                   21(84.0)               50 (92.6)                    
   NI                                           1 (0.9)                      1 (2.7)                     0                      0                            
  **Family history of breast/ovarian cancer**                                                                                                                
   Yes                                          47 (40.5)                    18 (48.6)                   9 (36.0)               20 (37.0)                    0.299^[b)](#tfn2-crt-2016-135){ref-type="table-fn"}^
   No                                           65 (56.0)                    16 (43.2)                   15 (60.0)              34 (63.0)                    
   NI                                           4 (3.4)                      3 (8.1)                     1 (4.0)                0                            

Values are presented as number (%). VUS, variant of uncertain significance; SD, standard deviation; FIGO, International Federation of Gynecology and Obstetrics; NI, not indicated.

ANOVA test,

Chi-square Pearson's test.

###### 

Overall response rates after first chemotherapy in *BRCA1/2*-positive and sporadic epithelial ovarian cancer patients

                        No. of patients   Complete and partial response   p-value
  --------------------- ----------------- ------------------------------- ------------------------------------------------------
  *BRCA1/2* mutation    37                31 (83.8)                       0.898^[a)](#tfn3-crt-2016-135){ref-type="table-fn"}^
  *BRCA1/2* VUS         25                22 (88.0)                       
  *BRCA1/2* wild type   54                46 (85.2)                       

Values are presented as number (%). VUS, variant of uncertain significance.

Chi-square Pearson's test.

###### 

Frequently observed *BRCA1/2* mutations

  Gene      Site      Mutation                                       Mutation type   No. (%) (n=37)   BIC data
  --------- --------- ---------------------------------------------- --------------- ---------------- ----------
  *BRCA1*   Exon 11   c.3627_3628insA (p.Leu1209_Glu1210?fs)         Frameshift      5 (13.5)         Yes
  *BRCA1*   Exon 7    c.390C\>A (p.Tyr130Ter)                        Nonsense        3 (8.1)          Yes
  *BRCA1*   Exon 10   c.1399A\>T (p.Lys467Ter)                       Nonsense        2 (5.4)          Yes
  *BRCA1*   Exon 11   c.4041_4042delAG (p.Arg1347_Gly1348ArgAsnfs)   Frameshift      2 (5.4)          Yes
  *BRCA1*   Exon 11   c.3442delG (p.Glu1148Argfs)                    Frameshift      2 (5.4)          Yes
  *BRCA2*   Exon 15   c.7480C\>T(p.Arg2494Ter)                       Nonsense        2 (5.4)          Yes

BIC, Breast Cancer Information Core.

###### 

Frequently observed *BRCA1/2* VUSs

  Gene      Site      Mutation                    Mutation type   No. (%) (n=25)   BIC data
  --------- --------- --------------------------- --------------- ---------------- ----------
  *BRCA2*   Exon 18   c.8187G\>T (p.Lys2729Asn)   Missense        4 (16.0)         Yes
  *BRCA1*   Exon 16   c.5339T\>C(p.Leu1780Pro)    Missense        3 (12.0)         Yes
  *BRCA1*   Exon 16   c.4883T\>C (p.Met1628Thr)   Missense        2 (8.0)          Yes

VUS, variant of uncertain significance; BIC, Breast Cancer Information Core.
